Replies to post #390331 on Elite Pharmaceuticals Inc (ELTP)

[NASDAQ2020]

This is the 21st century
Need to get up to date
This is where we are now entering combined IMS markets of $10+ BILLION

X 1. Cash Flow Positive Status - 5 years
X 2. Purchase building which houses their cGMP registered facility for research, development, manufacturing and packaging of pharmaceutical products.
X 3. Adderall IR $335 Million launched
X 4. In house marketing and distribution: Kirkov
X 5. Generic OxyContin- FIRST TO FILE Aug 17, 2023 $720 Million
—6. Full ownership of Adderall XR $ 1.56 Billion launched
—7. Generic Concerta- $1.2 BILLION
—8. Generic Vyvanse- $5.3 BILLION
—9. Vigabatrin - VigPoder approved Pyros $233 Million
—10.Dopamine Agonist (probably Requip XL or Mirapex ER). $12 Million
—11. Patented Unique ADF (w/o naltrexone)-- NDA
—12. Mikah ANDA (s)
—13. Undisclosed (s)
—14. Antimetabolite ANDA- Methotrexate -$600 Million
—15. Undisclosed Antimetabolite ANDA- $42 Million
—16. Prasco/Burel Adderall agreement January 1st 2024
—17. European distribution Dexcel partnership approval by Israeli Health
—18. Purchase or rent additional manufacturing space for new ANDAs
—19. Uplisting to the NASDAQ Exchange
—20. THE BuyOut
Bullish
ELTP